Omiloxetine

Omiloxetine
Clinical data
ATC code	None;
Identifiers
	IUPAC name 2-[(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)ethanone;
CAS Number	176894-09-0;
PubChem CID	3047803;
ChemSpider	2310120;
UNII	H8YI0SSF7B;
ChEMBL	ChEMBL2105290;
CompTox Dashboard (EPA)	DTXSID30170205 ;
Chemical and physical data
Formula	C27H25F2NO4
Molar mass	465.489 g/mol g·mol−1
3D model (JSmol)	Interactive image;
Density	1.3±0.1 g/cm3
Melting point	228.65 °C (443.57 °F)
Boiling point	587.2 °C (1,089.0 °F)
Solubility in water	0.0015 mg/mL (20 °C)
	SMILES Fc1ccc(cc1)C(=O)CN3CC[C@H](c2ccc(F)cc2)[C@H](C3)COc4ccc5OCOc5c4;
	InChI InChI=1S/C27H25F2NO4/c28-21-5-1-18(2-6-21)24-11-12-30(15-25(31)19-3-7-22(29)8-4-19)14-20(24)16-32-23-9-10-26-27(13-23)34-17-33-26/h1-10,13,20,24H,11-12,14-17H2/t20-,24-/m1/s1; Key:FAHGZANUNVVDFL-HYBUGGRVSA-N;

Omiloxetine (omiloextinum, omiloxetino INN)^[1]^{: 212–213} was a selective serotonin reuptake inhibitor drug candidate that underwent preclinical development by the Spanish pharmaceutical company, Ferrer Internacional, until 2005, when it was abandoned.^[2]^[3]

References

^ WHO Drug Information, Vol. 10, No. 4, 1996 Proposed INN: List 76
^ Terencio, Jose (2005-12-05). "Omiloxetine - Ferrer licensing offer, worldwide". R & D Focus Drug News. Retrieved 2012-05-19.
^ De Lecea, Dr Carlos (2003-12-08). "Omiloxetine - Ferrer partnering opportunity, worldwide Ferrer preclinical data". R & D Focus Drug News. Retrieved 2012-05-19.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[1] WHO Drug Information, Vol. 10, No. 4, 1996 Proposed INN: List 76

[Terencio2005-2] Terencio, Jose (2005-12-05). "Omiloxetine - Ferrer licensing offer, worldwide". R & D Focus Drug News. Retrieved 2012-05-19.

[Lecea2003-3] De Lecea, Dr Carlos (2003-12-08). "Omiloxetine - Ferrer partnering opportunity, worldwide Ferrer preclinical data". R & D Focus Drug News. Retrieved 2012-05-19.

[1]

[2]

[3]